| Carcinoma breast stage IV
Phesgo vs Verzenio
Side-by-side clinical, coverage, and cost comparison for carcinoma breast stage iv.Deep comparison between: Phesgo vs Verzenio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVerzenio has a higher rate of injection site reactions vs Phesgo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Verzenio but not Phesgo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Phesgo
Verzenio
At A Glance
SC injection
Every 3 weeks
HER2/neu receptor antagonist
Oral
Twice daily
CDK4/6 inhibitor
Indications
- HER2-positive carcinoma of breast
- Inflammatory Breast Carcinoma
- Locally advanced breast cancer
- Carcinoma breast stage IV
- Malignant neoplasm of breast
- Carcinoma breast stage IV
Dosing
HER2-positive carcinoma of breast, Inflammatory Breast Carcinoma, Locally advanced breast cancer Initial dose 1,200 mg pertuzumab / 600 mg trastuzumab / 30,000 units hyaluronidase SC over ~8 min, then maintenance 600 mg pertuzumab / 600 mg trastuzumab / 20,000 units hyaluronidase SC over ~5 min every 3 weeks with chemotherapy; neoadjuvant: 3-6 preoperative cycles then continue to complete 18 total cycles; adjuvant: up to 18 cycles (1 year) starting Day 1 of first taxane-containing cycle.
Carcinoma breast stage IV Initial dose 1,200 mg pertuzumab / 600 mg trastuzumab / 30,000 units hyaluronidase SC over ~8 min, then maintenance 600 mg pertuzumab / 600 mg trastuzumab / 20,000 units hyaluronidase SC over ~5 min every 3 weeks with docetaxel until disease progression or unmanageable toxicity.
Malignant neoplasm of breast 150 mg orally twice daily in combination with tamoxifen or an aromatase inhibitor for 2 years as adjuvant treatment (or until disease recurrence or unacceptable toxicity).
Carcinoma breast stage IV 150 mg orally twice daily in combination with an aromatase inhibitor (initial therapy) or fulvestrant (after endocrine therapy progression); 200 mg orally twice daily as monotherapy (after endocrine therapy and prior chemotherapy); continue until disease progression or unacceptable toxicity.
Contraindications
- Known hypersensitivity to pertuzumab, trastuzumab, hyaluronidase, or any excipient of PHESGO
—
Adverse Reactions
Most common (>=5%) Alopecia, nausea, diarrhea, anemia, asthenia, fatigue, stomatitis, myalgia, arthralgia, neutropenia, vomiting, constipation, headache, dysgeusia, decreased appetite, peripheral sensory neuropathy, mucosal inflammation, injection site reaction, radiation skin injury, insomnia, cough
Serious Febrile neutropenia, neutropenic sepsis, neutrophil count decreased, cardiomyopathy, pulmonary toxicity
Postmarketing Glomerulopathy, immune thrombocytopenia, tumor lysis syndrome
Most common (>=20%) diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, alopecia, thrombocytopenia
Serious neutropenia, diarrhea, interstitial lung disease/pneumonitis, hepatotoxicity, venous thromboembolism
Postmarketing interstitial lung disease/pneumonitis
Pharmacology
Pertuzumab blocks HER2 heterodimerization at subdomain II to inhibit MAP kinase and PI3K signaling, trastuzumab binds subdomain IV to inhibit HER2-mediated cell proliferation, and together they augment antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor cells; hyaluronidase transiently depolymerizes hyaluronan to increase subcutaneous tissue permeability and enable systemic absorption.
Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6); in ER-positive breast cancer cells, it blocks Rb phosphorylation and cell cycle progression from G1 into S phase, resulting in senescence and apoptosis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Phesgo
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
Verzenio
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Phesgo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Verzenio
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Phesgo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Verzenio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PhesgoView full Phesgo profile
VerzenioView full Verzenio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.